DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university.
The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. The work will be conducted in the Company's state-of-the-art process development lab and cGMP cleanrooms in its Mammalian Building, which is ideally suited for early-stage programs using CHO cell lines. Following process optimization and development, the Company expects to expand the scope of the agreement to include Phase 1 clinical manufacturing.
Jeff Wolf, CEO of Scorpius, stated, "Scorpius is excited to begin work with another nationally renowned university. Our selection by this leading researcher highlights our unique process development, bioanalysis, and manufacturing capabilities, which we have the ability to leverage into much larger projects as the programs progress through clinical stages and eventually into commercialization. There is a tremendous amount of innovative ...